- Clone
- R24.Rec (See other available formats)
- Regulatory Status
- RUO
- Other Names
- GD3S, SIAT8, Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase, SIAT8-A, ganglioside GD3 synthase, sialytransferase St8Sia I, alpha-2, 8-sialyltransferase 8A, disialoganglioside (GD3) synthase, ganglioside-specific alpha-2, 8-polysialyltransferase
- Isotype
- Mouse IgG1, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Save |
---|---|---|---|
638851 | 25 µg | ¥37,400 | |
638852 | 100 µg | ¥97,900 |
GD3, also known as MEL-1, is a ganglioside found in almost all melanomas and is an important biomarker for malignant melanoma. GD3 is found in melanocytes and other cells that originate in the neuroectoderm. Anti-GD3 antibodies have been shown to induce partial remission of tumor growth due to the proliferation of cytotoxic lymphocytes. GD3 is synthesized by the enzyme ST8SIA1.
Product DetailsProduct Details
- Verified Reactivity
- Human
- Antibody Type
- Recombinant
- Host Species
- Mouse
- Immunogen
- This antibody was raised against SK-MEL-28 melanoma cell line.
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/mL
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C.
- Application
-
IHC-F - Quality tested
ICC, ICFC - Verified - Recommended Usage
-
Each lot of this antibody is quality control tested by immunohistochemical staining on frozen tissue sections. For immunohistochemistry, a concentration range of 1.0 - 5.0 µg/mL is suggested. For immunocytochemistry, a concentration range of 1.0 - 10.0 μg/mL is recommended. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
-
For use of this antibody (clone R24.Rec) in immunocytochemistry (ICC), we recommend fixation with Fixation Buffer (Cat. No. 420801), followed by permeabilization with 0.5% Triton-X. We do not recommend fixation with Fixation Buffer (Cat. No. 420801) followed by permeabilization with ice-cold methanol, nor fixation/permeabilization with ice-cold methanol alone.
For use of this antibody (clone R24.Rec) in intracellular flow cytometry (ICFC), we recommend fixation/permeabilization with Cyto-Fast™ Fix/Perm Buffer Set (Cat. No. 426803).
This antibody (clone R24.Rec) is not suitable for use in immunohistochemistry with formalin-fixed, paraffin-embedded tissues (IHC-P). - RRID
-
AB_3662322 (BioLegend Cat. No. 638851)
AB_3662322 (BioLegend Cat. No. 638852)
Antigen Details
- Structure
- A ganglioside is comprised of a glycosphingolipid and one or more sialic acid groups.
- Distribution
-
Cytoplasmic, ER/Golgi, secreted
- Function
- Cellular recognition, cell/cell signaling
- Biology Area
- Cancer Biomarkers
- Antigen References
-
- Meidenbauer N, et al. 2004. Cancer Res. 64: 6319-26.
- Kasahara K, et al. 2000. J Biol Chem. 275: 34701-9.
- Watarai S, et al. 1991. J Biochem. 110:889-95.
- Yuyama K, et al. 2007. J. Biol. Chem. 282: 26392-400.
- Gene ID
- NA
- UniProt
- View information about GD3 on UniProt.org
Related Pages & Pathways
Pages
Related FAQs
Other Formats
View All GD3 Reagents Request Custom ConjugationDescription | Clone | Applications |
---|---|---|
Purified anti-GD3 (MEL-1) Recombinant Antibody | R24.Rec | IHC-F,ICC,ICFC |
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
-
Purified anti-GD3 (MEL-1) Recombinant Antibody
IHC staining of Purified anti-GD3 (MEL-1) (clone R24.Rec) on... SK-MEL-28 cells were fixed with 4% PFA Fixation Buffer (Cat.... SK-Mel-28 cells (positive control, filled histogram) and HeL...
Follow Us